Pancreatic Cancer Research

ResearcherUniversité de BordeauxActive in the last 2 years

Antoîne Italiano

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-8540-5351; OpenAlex author ID A5060949051. Sources: ClinicalTrials.gov.

Their work

Papers
7
Trials
1
Grants
0
Labs led
0
Collaborators
41
Papers, trials and grants by year

2015: 1 trial · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: none · 2024: 3 papers · 2025: 1 paper · 2026: 3 papers

Papers 7

  1. Integrating tumor volumetry and liquid biopsy: a New model to define prognosis in advanced pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ejca.2026.116768↗
  2. Setidegrasib in Advanced Non-Small-Cell Lung Cancer and Pancreatic Cancer. Co-author DOI 10.1056/nejmoa2600752↗
  3. Cell-free chromatin epigenomic profiling enables non-invasive pancreatic cancer cell-state identification Co-author DOI 10.64898/2026.04.02.26349987↗
  4. Extensive molecular profiling of KRAS wild-type as compared to KRAS mutated pancreatic ductal adenocarcinoma on 318 patients. Co-author DOI 10.1016/j.ejca.2024.115197↗
  5. Codon-specific KRAS mutations predict survival in advanced pancreatic cancer. Co-author DOI 10.1016/j.esmogo.2023.100030↗
  6. Organoids for Functional Precision Medicine in Advanced Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2024.05.032↗
  7. Echoendoscopic ultrasound pancreatic adenocarcinoma diagnosis and theranostic approach: should KRAS mutation research be recommended in everyday practice? Co-author DOI 10.1177/17562848231224943↗

Trials 1

  1. Bergonie Institut Profiling : Fighting Cancer by Matching Molecular Alterations and Drugs in Early Phase Trials Study chair NCT02534649↗

Closest collaborators

The 25 strongest of 41 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Antoine Hollebecque · 5 shared papers, 2024–2026 · strength 0.90
  2. Anthony Tarabay · 3 shared papers, 2024–2026 · strength 0.52
  3. Cristina Smolenschi · 3 shared papers, 2024–2026 · strength 0.52
  4. Alice Boilève · 3 shared papers, 2024–2026 · strength 0.52
  5. Michel Pierre Ducreux · 3 shared papers, 2024–2026 · strength 0.52
  6. Jeanne Léna · 2 shared papers, 2024–2025 · strength 0.46
  7. Simon Pernot · 2 shared papers, 2024–2025 · strength 0.46
  8. Lola‐Jade Palmieri · 2 shared papers, 2024–2025 · strength 0.46
  9. David Malka · 2 shared papers, 2024 · strength 0.30
  10. Fanny Jaulin · 2 shared papers, 2024 · strength 0.30
  11. Victor Robic · 1 shared paper, 2026 · strength 0.22
  12. Nathalie Lassau · 1 shared paper, 2026 · strength 0.22
  13. Marianne Fonck · 1 shared paper, 2024 · strength 0.21
  14. Dominique Béchade · 1 shared paper, 2024 · strength 0.21
  15. Gilles Roseau · 1 shared paper, 2024 · strength 0.21
  16. Wungki Park · 1 shared paper, 2026 · strength 0.19
  17. Hirokazu Shoji · 1 shared paper, 2026 · strength 0.19
  18. Makoto Ueno · 1 shared paper, 2026 · strength 0.19
  19. Anup Kasi · 1 shared paper, 2026 · strength 0.19
  20. Patricia Mucci LoRusso · 1 shared paper, 2026 · strength 0.19
  21. Jordan D. Berlin · 1 shared paper, 2026 · strength 0.19
  22. Pasi Antero Janne · 1 shared paper, 2026 · strength 0.19
  23. Christos K Fountzilas · 1 shared paper, 2026 · strength 0.19
  24. Philippe Alexandre Cassier · 1 shared paper, 2026 · strength 0.19
  25. Jonathan Wade Goldman · 1 shared paper, 2026 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.